Trial Profile
A prospective study to evaluate the combination of everolimus and exemestane in patients with ER+ advanced breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 14 Dec 2015 New trial record